ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc.

ORICNYSE / NASDAQHealthcareSmall cap

$7.36-$0.34 (-4.4%)

Last close · Data as of Nov 20, 2026

Market cap
$830.2M
P/E
-6.4x
EV / EBITDA
-5.6x
Revenue
$0.00
ROCE
-36.8%

-35.9% over the last year

ORIC Pharmaceuticals, Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-46.6%
3M
-47.0%
6M
-12.5%
1Y
-35.9%
5Y
-55.4%

52-week range

Day change -$0.34 (-4.4%) from $7.70 to $7.36 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in ORIC, bought on each weekday since 2021.

News & filings

What ORIC Pharmaceuticals filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 129 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are more than ten times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.

Read moreShow less

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozertinib formerly known as ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, that selectively target epidermal growth factor receptor (EGFR) exon 20 and human epidermal growth factor receptor 2 exon 20 with high potency towards exon 20 insertion mutations; and rinzimetostat formerly known as ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study. It has a clinical trial collaboration and supply agreement with Bayer to evaluate ORIC-944 in combination with Nubeqa AR inhibitor; and a clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC 944 in combination with Erleada AR inhibitor. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Sector
Healthcare
Shares outstanding
98.5M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$830.2M
P/E
-6.4x
P/B
2.2x
EV / EBITDA
-5.6x
52-week high
$14.65
52-week low
$7.36

Profitability

ROE
-33.7%
ROCE
-36.8%
ROIC
-33.0%
ROA
-31.7%

Growth

Revenue
$0.00
Net profit growth, 1Y
1.3%
Free cash flow
-$111.7M

Solvency

Current ratio
14.13
Debt / Equity
0.01
Debt / Assets
0.01
CFO / Net profit
0.86
Cash / Market cap
5.5%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

ORIC Pharmaceuticals, Inc. revenue and net profit by fiscal year
ORIC Pharmaceuticals, Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$0.00-$89.1M
FY2023$0.00-$100.7M
FY2024$0.00-$127.8M
FY2025$0.00-$129.5M

Cash flows

FY2025: -$111.0M from operations, -$111.7M free after investment (dashed).

ORIC Pharmaceuticals, Inc. operating and free cash flow by fiscal year
ORIC Pharmaceuticals, Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$75.1M-$77.2M
FY2023-$85.7M-$86.5M
FY2024-$112.7M-$113.8M
FY2025-$111.0M-$111.7M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$141.8M
Net profit
-$129.5M
Cash from operations
-$111.0M
Free cash flow
-$111.7M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$141.8M-$129.5M-$111.7M-33.7%—+1.3%

Monthly returns

Month-by-month returns of ORIC across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$408.9M
Liabilities$24.5M
Equity$384.4M
Paid-in capital$1.1B
Retained earnings-$692.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; ORIC highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): ORIC Pharmaceuticals, Inc., LB Pharmaceuticals Inc, Sana Biotechnology, Inc., Replimune Group, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
ORIC Pharmaceuticals, Inc.ORICthis company$830.2M-6.4x2.2x-33.7%-5.6x
Arbutus Biopharma CorporationABUS$859.3M-25.6x11.2x-43.7%-25.5x
Theravance Biopharma, Inc.TBPH$843.9M8.0x2.8x35.7%5.3x
Janux Therapeutics, Inc.JANX$839.1M-7.4x0.9x-11.9%-5.2x
LB Pharmaceuticals IncLBRX$828.8M-32.9x2.8x-8.4%-19.4x
Amphastar Pharmaceuticals, Inc.AMPH$824.5M8.4x1.0x12.4%6.2x
Sana Biotechnology, Inc.SANA$823.7M-3.4x5.1x-151.8%-4.3x
Replimune Group, Inc.REPL$815.0M-3.3x2.0x-59.5%-3.3x
Esperion Therapeutics, Inc.ESPR$805.8M——7.5%13.9x
Peer median—-3.4x2.8x-10.1%-3.8x

Year-to-date ROI

ORIC since 1 January, against earlier years.

Historical volatility

ORIC's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

LineFY2025
Operating expensesOperating Expense$143.0M
Research and developmentResearch And Development$109.8M
Total expensesTotal Expenses$143.0M
Pretax incomePretax Income-$129.5M

Learn while you research

Academy chapters picked for ORIC Pharmaceuticals, Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →